Online inquiry

IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8083MR)

This product GTTS-WQ8083MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Dermatomyositis, Nephritis, Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8083MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1278MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ1212MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ7565MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ8241MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ13205MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ9808MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ2074MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ532MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 4D11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW